COVID-19 in patients with primary immunodeficiency

Area of Science:

• Immunology
• Infectious Diseases
• Genetics

Background:

• Primary immunodeficiencies (PIDs) comprise diverse genetic and immunological conditions.
• PIDs predispose individuals to infections, posing challenges during the SARS-CoV-2 pandemic.
• The pandemic has highlighted unique risks and management needs for PID patients.

Purpose of the Study:

• To review and update the understanding of SARS-CoV-2 infections and COVID-19 outcomes in patients with PIDs.
• To analyze the factors contributing to severe disease and mortality in PID patients infected with SARS-CoV-2.

Main Methods:

• Literature review of published data on SARS-CoV-2 and COVID-19 in PID patients.
• Analysis of reported cases focusing on disease progression, severity, and mortality.
• Examination of immunological factors, including type I interferon immunity, and comorbidities.

Main Results:

• Most severe COVID-19 morbidity and mortality in PID patients are associated with pre-existing comorbidities (e.g., bronchiectasis, diabetes) rather than the specific PID.
• A subset of PID patients exhibits impaired type I interferon immunity, increasing susceptibility to severe COVID-19.
• Outcomes vary significantly depending on the specific PID and associated health conditions.

Conclusions:

• While PIDs confer susceptibility, severe SARS-CoV-2 outcomes are often driven by non-immunological factors.
• Impaired type I interferon responses represent a specific risk factor in some PID patients.
• Comprehensive management strategies considering comorbidities are crucial for mitigating COVID-19 severity in PID populations.